We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Self-Expanding Intracoronary Prosthesis Limits Arterial Injury

By HospiMedica staff writers
Posted on 12 Jun 2008
A self-expanding luminal shield is designed to limit the arterial injury that typically occurs when cardiac stents are deployed. More...


The vProtect luminal shield is designed to treat soft, atherosclerotic lesions that may be at risk of rupture, or recently ruptured. The vProtect has ultra-thin struts to promote healing, and maintains an intrinsic radial force that matches the vessel compliance. The shield also provides robust biocompatible support for the vessel to ensure that the target coronary artery will remain open after placement. Three patients with established cardiac ischemia became the first recipients of the vProtect luminal shield in surgery performed in Columbia during May 2008. In the first patient, a 75% occlusion in the mid-circumflex coronary artery underwent pre-dilatation at low pressure with a 2.5 x 9 mm balloon and then received a 3.5 x 15 mm luminal shield. After gentle post-dilatation, angiography revealed that blood flow had been restored to the distal portion of the treated vessel. In the second patient, an 80% occlusion in the middle of the left anterior descending (LAD) branch required pre-dilatation with a 2.5 x 9 mm balloon. Additional lumen gain was achieved by shield placement and post-dilatation, again achieving restoration of blood flow distal to the treated segment.

The third patient was a challenging case with a 65% occlusion in the mid-LAD, located in a bend near a side branch ostium. The vProtect was chosen for this patient based on its mechanical properties, including high vascular conformability. Because of its flexibility, the vProtect was able to access the tortuous anatomy and cross the lesion successfully. Restoration of blood flow was achieved without angiographic evidence of straightening of the target vessel, a common occurrence with rigid balloon-expandable stents. In addition, the side branch was preserved without evidence of plaque shifting or worsening stenosis. The vProtect Luminal Shield is being developed by Prescient Medical (Doylestown, PA, USA), and is currently limited by U.S. federal law to investigational use only.

"The vProtect luminal shield and delivery system performed extremely well,” said Juan F. Granada, M.D., of the Cardiovascular Research Foundation (New York, NY; USA) who performed the surgery together with Juan Delgado, M.D., at the Corbic Institute-MUA (Envigado [near Medellin], Colombia). "The three patients we treated presented with lesions representative of what we see in daily clinical practice and we were able to cross these lesions and deliver the device safely in each case.”


Related Links:
Prescient Medical
Corbic Institute-MUA

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Head Rest
Medifa 61114_3
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.